Molina Healthcare Inc. (US60855R1005) stock is changing hands close to analyst expectations, with shares quoted at $199.79 in recent trading on August 26, 2026, while forecasts describe 2026 as a trough year for the managed care specialist with the potential for earnings improvement thereafter. Recent trading data also show institutional investors incrementally increasing positions, underscoring continued interest in the company despite pressure on recent results.
Shares hover around $200 as of late August 2026
According to a detailed trading snapshot dated August 26, 2026, Molina Healthcare stock opened at $199.79 on the New York Stock Exchange under the ticker MOH, placing the stock slightly below the $203.44 closing price recorded on August 24, 2026, for a modest pullback of $3.65 over those two sessions. A valuation overview from August 24, 2026, indicated that the shares then traded at $203.44 and at 28.1 times forward earnings, giving investors a concrete sense of how the market prices the company’s growth prospects at current levels.
The same valuation snapshot highlighted that the $203.44 share price on August 24, 2026, sat just $1.00 above a consensus price target of $202.44, suggesting that Molina Healthcare stock was trading almost exactly in line with the collective view from covering analysts at that point. More recent institutional-ownership updates published on August 26, 2026, reiterate the same consensus target of $202.44, reinforcing the impression that the current price zone near $200 reflects a market stance that sees neither a deep discount nor a significant premium to expected value.
Recent quarterly results and 2026 trough-year guidance
On the fundamental side, recent quarterly results show that Molina Healthcare is currently working through a weaker earnings phase in 2026. In the latest reported quarter, the company generated earnings per share of $1.51, exceeding the consensus estimate of $1.39 by $0.12, according to a research note dated August 25, 2026 that summarized the latest figures and analyst revisions. That same summary noted that revenue for the period came in at $10.87 billion, slightly ahead of the $10.83 billion level analysts had expected.
Despite this modest earnings beat versus consensus, the same quarter showed a 4.8 percent year-over-year decline in revenue, illustrating that Molina Healthcare is currently facing top-line headwinds compared with the prior-year period. A separate portfolio analysis published on August 25, 2026 framed the situation more starkly, indicating that in the second quarter premium revenue fell 6 percent, net income declined 76 percent, and the medical-cost ratio worsened to 92.2 percent, all of which underscore the pressure on profitability in 2026. The same analysis highlighted that management describes 2026 as a trough year and guides to at least $5.25 of adjusted earnings per share.
That trough-year guidance provides a quantitative anchor for valuation: at a trading level of $199 per share, the portfolio analysis calculated that the stock was 38 times the $5.25 trough-year adjusted EPS guidance, a multiple that investors may view as demanding given the currently depressed profitability. The discussion further argued that if adjusted earnings per share were to normalize back into a range of $12 to $14 and the market were to award a 14 times earnings multiple to those normalized earnings, then an illustrative fair value range would be $168 to $196, compared with the current market level around $199. While such scenario-based estimates are inherently uncertain, they frame how some investors are balancing trough-year weakness against the possibility of a later rebound.
Analyst consensus and estimate revisions
Short-term estimate revisions underline that the earnings outlook remains under scrutiny. A fresh research update summarized on August 25, 2026 reported that one analyst team had trimmed its forecast for an upcoming quarter’s earnings from $0.72 per share to $0.71, reflecting a cautious stance even after the recent $1.51 EPS result beat the $1.39 consensus for the latest quarter. This estimate cut suggests that at least some forecasters are fine-tuning their models to reflect the combination of medical-cost trends and top-line softness observed so far in 2026.
At the same time, several institutional-holding updates published on August 25 and 26, 2026, all citing the same underlying consensus data, point out that Molina Healthcare continues to carry an average rating of Hold and a consensus price target of $202.44. These reports show that asset managers have been adding or initiating positions while relying on the same consensus target, which sits only fractionally above the $199 to $203 trading band seen around August 24 to August 26, 2026. For investors, the narrow gap between the market price and the consensus target underscores that much of the current trough-year narrative may already be reflected in the valuation.
Valuation context and peer comparison
A broader sector snapshot collected on August 26, 2026, that listed Molina Healthcare alongside other US health names cited the stock at $199.63 with a market capitalization of $10.421 billion, essentially confirming the sub-$200 level referenced in more detailed coverage while also providing a sense of the company’s scale within the managed care universe. In that same overview, Molina Healthcare appeared in a peer list next to another health-insurance player, illustrating how investors may compare metrics like revenue growth and profitability across the space even though the detailed figures presented there pertained to a different issuer.
Relative to this scale and valuation, the previously cited 28.1 times forward earnings multiple from the August 24, 2026 snapshot stands out, as it positions Molina Healthcare stock at a noticeably higher multiple than many value-focused investors might favor in a period labeled as a trough year. The interplay between a forward multiple above 28, trough-year adjusted EPS guidance of at least $5.25, and scenario-based normalized EPS in the $12 to $14 range provides a numerical framework for assessing whether the current trading range around $200 leaves room for upside if margins recover or instead bakes in much of that potential already.
Medicaid-focused managed care model
Molina Healthcare’s business model centers on managing government-sponsored health plans, with a focus on Medicaid and related programs, where the company receives per-member-per-month premiums in exchange for coordinating and paying for care. This model links profitability closely to medical-cost ratios: as the portfolio analysis noted for the latest quarter, a medical-cost ratio of 92.2 percent indicates that more than ninety cents of each premium dollar flowed out as claims, leaving a narrow margin to cover administrative costs and generate profit.
In practice, Molina Healthcare seeks to improve this margin equation by refining care-management programs, negotiating provider rates, and optimizing the mix of members and contracts across states. When medical-cost ratios improve, even modestly, the impact on earnings can be substantial because small changes in percentage points apply to a multibillion-dollar revenue base; conversely, as the recent deterioration to a 92.2 percent ratio illustrates, adverse cost trends can compress earnings quickly despite stable or only slightly lower revenues.
Representative Medicaid health plan offering
One representative product in Molina Healthcare’s portfolio is its Medicaid health plan coverage in various US states, which typically offers eligible low-income individuals access to a defined network of physicians, hospitals, and specialists alongside benefits such as preventive care, maternity services, and prescription-drug coverage. These plans are structured under state contracts where Molina Healthcare agrees to manage the care of enrolled members for a predetermined premium, making accurate pricing of medical risk essential to maintaining sustainable margins.
In many markets, these Medicaid plans also incorporate care-coordination features such as nurse hotlines, disease-management programs for chronic conditions like diabetes or COPD, and digital tools that help members locate providers and schedule appointments. Because state agencies evaluate performance based on measures such as quality scores, member satisfaction, and cost effectiveness, Molina Healthcare’s ability to deliver strong outcomes in these Medicaid products directly influences its prospects for winning contract renewals and expanding enrollment in future bid cycles.
Molina Healthcare stock and recent trading context
Molina Healthcare stock is listed on the New York Stock Exchange under the ticker MOH, and the trading snapshots from August 24 to August 26, 2026, show the shares changing hands within a tight band between $199.79 and $203.44 in US dollars. With the consensus analyst target at $202.44 and the stock recently quoted at $199.79 and $199.63 in separate market overviews, the shares are trading slightly below to marginally above that reference point, a range that suggests the market price is broadly aligned with prevailing earnings and valuation expectations.
For investors, the central numerical tension is clear: management frames 2026 as a trough year with guided adjusted earnings per share of at least $5.25, the most recent quarter delivered $1.51 in EPS on weaker revenues and a 92.2 percent medical-cost ratio, and the market currently values the stock in the region of 28.1 times forward earnings around the $200 mark. As long as those figures define the story, Molina Healthcare stock is likely to be judged on whether medical-cost trends stabilize and earnings move toward the higher, normalized levels implied by scenario analyses, all while the price remains anchored close to the consensus target of $202.44 as of late August 2026.
Read more
More on Molina Healthcare stock valuation
Medicaid plans as a core franchise
Molina Healthcare’s Medicaid plans represent a core franchise because they channel large volumes of members through capitated contracts where the company bears medical-cost risk in exchange for recurring premium revenue. In states where Molina Healthcare manages these plans, it typically partners with local provider networks and community organizations to deliver services, an approach that can help align incentives around preventive care and avoidable hospitalizations.
As public health agencies and policymakers refine Medicaid programs, they often introduce new quality metrics and value-based payment structures that influence how companies like Molina Healthcare are compensated. The success of Molina Healthcare’s Medicaid products therefore depends not only on actuarial pricing and medical-cost management but also on its ability to meet evolving quality benchmarks and demonstrate improved outcomes for vulnerable populations, which in turn can strengthen its position in future procurement processes.
Current trading level and investor takeaway
As of the most recent data points around August 24 to August 26, 2026, Molina Healthcare stock has been quoted between $199.63 and $203.44 on the New York Stock Exchange, with an opening price of $199.79 documented on August 26, 2026. These levels align closely with the consensus analyst price target of $202.44 and imply a forward price-to-earnings multiple of 28.1 based on prevailing forecasts, numbers that together indicate the stock is valued in line with current expectations of a trough year followed by a potential recovery in profitability.
Given guided adjusted earnings per share of at least $5.25 for 2026, the latest quarterly EPS of $1.51 on $10.87 billion in revenue, and a medical-cost ratio of 92.2 percent, investors evaluating Molina Healthcare stock at the current price band are effectively weighing whether margins and earnings can normalize toward the $12 to $14 EPS scenarios discussed in recent analysis, which suggest a fair value range of $168 to $196 under a 14 times earnings multiple. Against a live trading level near $200 as of late August 2026, that framework provides a quantified lens through which to interpret the stock’s risk-reward profile in the managed care sector.
Fact box
Company: Molina Healthcare Inc.
ISIN: US60855R1005
Ticker: MOH
Exchange: New York Stock Exchange
Price (as of August 26, 2026, opening price): $199.79 USD
Sector / Industry: Managed care / Health insurance
Disclaimer…